Serum tumor markers in testicular cancer

Yaron Ehrlich, Stephen D W Beck, Richard Foster, Richard Bihrle, Lawrence Einhorn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Testicular cancer has become a model for a curable neoplasm, where biochemical markers play a critical role. Serum tumor markers are integral in patient management and contributes to the diagnosis, staging, and risk assessment, as well as evaluation of response to therapy and detection of relapse. We review their biochemistry, biology, and clinical use in the setting of localized and metastatic disease. The integration of tumor markers in prognostic models as well as the significance of marker kinetics during chemotherapy is discussed.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Testicular Neoplasms
Tumor Biomarkers
Biomarkers
Biochemistry
Recurrence
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • Chemotherapy
  • Prognosis
  • Serum tumor markers
  • Testicular neoplasia

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Serum tumor markers in testicular cancer. / Ehrlich, Yaron; Beck, Stephen D W; Foster, Richard; Bihrle, Richard; Einhorn, Lawrence.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 31, No. 1, 01.2013, p. 17-23.

Research output: Contribution to journalArticle

@article{fa4815f9e9d541ec85b76b34574798c6,
title = "Serum tumor markers in testicular cancer",
abstract = "Testicular cancer has become a model for a curable neoplasm, where biochemical markers play a critical role. Serum tumor markers are integral in patient management and contributes to the diagnosis, staging, and risk assessment, as well as evaluation of response to therapy and detection of relapse. We review their biochemistry, biology, and clinical use in the setting of localized and metastatic disease. The integration of tumor markers in prognostic models as well as the significance of marker kinetics during chemotherapy is discussed.",
keywords = "Chemotherapy, Prognosis, Serum tumor markers, Testicular neoplasia",
author = "Yaron Ehrlich and Beck, {Stephen D W} and Richard Foster and Richard Bihrle and Lawrence Einhorn",
year = "2013",
month = "1",
doi = "10.1016/j.urolonc.2010.04.007",
language = "English",
volume = "31",
pages = "17--23",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Serum tumor markers in testicular cancer

AU - Ehrlich, Yaron

AU - Beck, Stephen D W

AU - Foster, Richard

AU - Bihrle, Richard

AU - Einhorn, Lawrence

PY - 2013/1

Y1 - 2013/1

N2 - Testicular cancer has become a model for a curable neoplasm, where biochemical markers play a critical role. Serum tumor markers are integral in patient management and contributes to the diagnosis, staging, and risk assessment, as well as evaluation of response to therapy and detection of relapse. We review their biochemistry, biology, and clinical use in the setting of localized and metastatic disease. The integration of tumor markers in prognostic models as well as the significance of marker kinetics during chemotherapy is discussed.

AB - Testicular cancer has become a model for a curable neoplasm, where biochemical markers play a critical role. Serum tumor markers are integral in patient management and contributes to the diagnosis, staging, and risk assessment, as well as evaluation of response to therapy and detection of relapse. We review their biochemistry, biology, and clinical use in the setting of localized and metastatic disease. The integration of tumor markers in prognostic models as well as the significance of marker kinetics during chemotherapy is discussed.

KW - Chemotherapy

KW - Prognosis

KW - Serum tumor markers

KW - Testicular neoplasia

UR - http://www.scopus.com/inward/record.url?scp=84873999469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873999469&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2010.04.007

DO - 10.1016/j.urolonc.2010.04.007

M3 - Article

C2 - 20822927

AN - SCOPUS:84873999469

VL - 31

SP - 17

EP - 23

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 1

ER -